Picture of Semnur Pharmaceuticals logo

SMNR Semnur Pharmaceuticals Share Price

0.000.00%
us flag iconLast trade - 00:00
HealthcareSpeculativeMid CapValue Trap

Momentum

Relative Strength (%)
1m-66.32%
3m-15.08%
6m-38.79%
1yr-44.86%
Volume Change (%)
10d/3mn/a
Price vs... (%)
52w High-65.22%
50d MA-38.51%
200d MA-17.57%

Growth & Value

Shareholder Activity

TypeBuy / Hold / Sell
Institutions
Directors
Community

Guru Screens

Quality

NameIndustryMarket
Return on Capitaln/a
Return on Equity-9.04%
Operating Marginn/a

Health Trend(F-Score)

12345678910

Bankruptcy Score(Z-Score)

Distress
Cautious
Safe

Earnings Manipulation Risk(M-Score)

Other Ratios

Leverage (ttm)Total- Intang+ Pension
Gross Gearing
Net Gearing
Cash / Assets

Recent History

Latest interim period vs. prior periodIndustryMarket
Sales Growth
EPS Growth
3yr Compound Annual Growth RateIndustryMarket
Sales CAGR
EPS CAGR
DPS CAGR

Graphical History

Revenue
Blurred out image of Revenue chart
Net Income
Blurred out image of Net Income chart
Normalised EPS
Blurred out image of Normalised EPS chart
PE Ratio Range
Blurred out image of PE Ratio Range chart
Dividend Yield Range
Blurred out image of Dividend Yield Range chart

Analyst Forecasts

Price target
( price)
31st Dec 202531st Dec 2026
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change

Analyst Consensus

Strong SellSellHoldBuyStrong Buy

EPS 2025 / 2026

Blurred out image of Semnur Pharmaceuticals EPS forecast chart

Profile Summary

Denali Capital Acquisition Corp. is a blank check company. The Company is formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses or entities. It has not selected any potential business combination target or initiated any substantive discussions, directly or indirectly, with any potential business combination prospects. The Company intends to identify a prospective target business will not be limited to a particular industry or geographic region. The Company intends to focus on identifying business within the technology, hospitality, or consumer services sector. The Company neither engaged in any operations nor generated any revenues.

Directors

    Last Annual
    December 31st, 2024
    Last Interim
    June 30th, 2025
    Incorporated
    January 5th, 2022
    Public Since
    January 1st, 1970
    No. of Shareholders
    11
    Sector
    Biotechnology & Medical Research
    Industry
    Healthcare
    Exchange
    us flag iconPink Sheets on Nasdaq
    Shares in Issue
    229,740,978
    Blurred out image of a map
    Address
    437 Madison Avenue, 27Th Floor, NEW YORK, 10022
    Web
    Phone
    Auditors
    Marcum LLP

    SMNR Share Price Performance

    Upcoming Events for SMNR

    Q4 2025 Semnur Pharmaceuticals Inc Earnings Release

    Similar to SMNR

    Picture of Actavia Life Sciences logo

    Actavia Life Sciences

    us flag iconPink Sheets on Nasdaq

    Picture of Acura Pharmaceuticals logo

    Acura Pharmaceuticals

    us flag iconPink Sheets on Nasdaq

    Picture of Adhera Therapeutics logo

    Adhera Therapeutics

    us flag iconPink Sheets on Nasdaq

    Picture of Ramoil Management logo

    Ramoil Management

    us flag iconPink Sheets on Nasdaq

    Picture of Adynxx logo

    Adynxx

    us flag iconPink Sheets on Nasdaq

    FAQ